Ribonucleotide reductase inhibitors as anti-herpes agents.
Ribonucleotide reductases (RNRs) supply the 2'-deoxyribonucleotide building blocks for DNA synthesis in mammalian cells and for herpes viruses. The viral-encoded RNRs have unique protein sequences that differ from mammalian enzyme primary structures. Selective inhibition of a viral RNR might provide an approach to new anti-herpes agents with minimal effects on the mammalian host RNRs. This review summarizes efforts to develop anti-herpes agents that selectively target viral-encoded RNRs.
Wnuk
Stanislaw F
SF
Department of Chemistry, Florida International University, University Park, Miami, FL 33199, United States.
Robins
Morris J
MJ
D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006561:Herpes Simplex / Q000188:drug therapy / Q000821:virology; D018259:Herpesvirus 1, Human / Q000187:drug effects* / Q000201:enzymology; D018258:Herpesvirus 2, Human / Q000187:drug effects* / Q000201:enzymology; D006801:Humans; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors* / Q000737:chemistry; D013882:Thiosemicarbazones / Q000737:chemistry / Q000494:pharmacology*
D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D013882:Thiosemicarbazones; D012264:Ribonucleotide Reductases